Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced solid tumours and multiple myeloma. The dosing was conducted at The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback